These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24324152)

  • 21. Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.
    Rashedi N; Taghizadeh M; Mohamadynejad P; Mahdavi M; Jalalirad R
    Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):497-508. PubMed ID: 33463117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.
    Son J; Lee SB; Lee DW; Kim IY; Lee SJ; Lee SM; Song SH; Seong EY; Kwak IS
    Clin Exp Nephrol; 2013 Apr; 17(2):275-83. PubMed ID: 22990301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvants in influenza vaccines.
    Tetsutani K; Ishii KJ
    Vaccine; 2012 Dec; 30(52):7658-61. PubMed ID: 23084848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity and dose determination of quillaja saponin, aluminum hydroxide and squalene in olive flounder (Paralichthys olivaceus).
    Vinay TN; Park CS; Kim HY; Jung SJ
    Vet Immunol Immunopathol; 2014 Mar; 158(1-2):73-85. PubMed ID: 23570990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
    Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
    J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
    Liang F; Lindgren G; Sandgren KJ; Thompson EA; Francica JR; Seubert A; De Gregorio E; Barnett S; O'Hagan DT; Sullivan NJ; Koup RA; Seder RA; Loré K
    Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
    Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
    Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant.
    van Aalst S; Ludwig IS; van der Zee R; van Eden W; Broere F
    PLoS One; 2017; 12(5):e0177365. PubMed ID: 28489886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.
    Zaharoff DA; Rogers CJ; Hance KW; Schlom J; Greiner JW
    Vaccine; 2007 Mar; 25(11):2085-94. PubMed ID: 17258843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
    Del Giudice G; Rappuoli R; Didierlaurent AM
    Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.
    Robinson C; Baehr C; Schmiel SE; Accetturo C; Mueller DL; Pravetoni M
    Hum Vaccin Immunother; 2019; 15(4):909-917. PubMed ID: 30625019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines.
    Stelzner JJ; Behrens M; Behrens SE; Mäder K
    Vaccine; 2018 Apr; 36(17):2314-2320. PubMed ID: 29567034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
    Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.
    Ellebedy AH; Lupfer C; Ghoneim HE; DeBeauchamp J; Kanneganti TD; Webby RJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2927-32. PubMed ID: 21270336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.
    Lai RP; Seaman MS; Tonks P; Wegmann F; Seilly DJ; Frost SD; LaBranche CC; Montefiori DC; Dey AK; Srivastava IK; Sattentau Q; Barnett SW; Heeney JL
    PLoS One; 2012; 7(4):e35083. PubMed ID: 22509385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmid DNA containing multiple CpG motifs triggers a strong immune response to hepatitis B surface antigen when combined with incomplete Freund's adjuvant but not aluminum hydroxide.
    Luo Z; Shi H; Zhang H; Li M; Zhao Y; Zhang J; Guo F; Luo S; Sun P; Zhang D; Qian Z; Yang L
    Mol Med Rep; 2012 Dec; 6(6):1309-14. PubMed ID: 22971976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and cellular signatures of human vaccine adjuvants.
    Mosca F; Tritto E; Muzzi A; Monaci E; Bagnoli F; Iavarone C; O'Hagan D; Rappuoli R; De Gregorio E
    Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10501-6. PubMed ID: 18650390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.